# A Study of Soticlestat in Adults and Children With Rare Epilepsies

> **NCT03635073** · PHASE2 · TERMINATED · sponsor: **Takeda** · enrollment: 156 (actual)

## Conditions studied

- Epilepsy
- Dravet Syndrome (DS)
- Lennox-Gastaut Syndrome (LGS)

## Interventions

- **DRUG:** Soticlestat

## Key facts

- **NCT ID:** NCT03635073
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-19
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-07-30
- **Target enrollment:** 156 (ACTUAL)
- **Why stopped:** Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-18-001 study is no longer necessary. Therefore, Takeda has made a decision to close this study
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03635073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03635073, "A Study of Soticlestat in Adults and Children With Rare Epilepsies". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03635073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*